Indivior To Present New Data At ISPOR And ICOO That Assess Implications Of Adherence, Healthcare Service Utilization And Costs In Opioid Use Disorder
SLOUGH, England, May 20, 2016 /PRNewswire/ -- Indivior PLC (LON: INDV) will unveil new real-world data that assess relapse and Buprenorphine Medication-Assisted Treatment (B-MAT) adherence rates and healthcare service utilization costs in addition to optimal minimal length of treatment, highlighting the company's continued dedication to ongoing research in opioid use disorder (OUD). Five posters will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual Meeting, to be held May 21-25, 2016 in Washington, DC along with two poster session presentations at the 2016 International Conference on Opioids (ICOO), June 5-7 in Boston, Massachusetts.
"While we as an industry have come a long way in understanding opioid use disorder as a real chronic medical disease, the ongoing epidemic shows that there remains a need to further advance the standard of care in this space1," said Dr. Tim Baxter, Chief Medical Officer, Indivior. "At Indivior we feel that data around identified characteristics of OUD patients, medication adherence and relapse rates, and potential barriers to treatment are imperative to develop comprehensive treatment plans for patients that remain effective long term."
Key data presentations at ISPOR highlight Indivior's new research aimed to help increase knowledge of and access to B-MAT as part of a holistic recovery plan, in conjunction with psychosocial care. Presentations include:
Monday, May 23, 2016, 3:45 p.m. 7:45 p.m.
- How To Measure 'Opioid Relapse' In Real-World Claims Data (Abstract PRM6)2
- This study was conducted in partnership with Truven Health Analytics and Aventura Family Health Center.
Tuesday, May 24, 2016, 8:30 a.m. 2:00 p.m.
- The Association Between Buprenorphine Medication Assisted Treatment Adherence And Healthcare Service Utilization And Costs (Abstract PMH31)3
- This study was conducted in partnership with Health Analytics, LLC; the Institute of Addiction Medicine; and Aetna Behavioral Health.
- This study was conducted in partnership with Health Analytics, LLC; the Institute of Addiction Medicine; and Aetna Behavioral Health.
- Relapse In Opioid Use Disorder: Implications For Health Care Utilization (Abstract PMH35)4
- This study was conducted in partnership with Health Analytics, LLC; the Institute of Addiction Medicine; and Aetna Behavioral Health.
- This study was conducted in partnership with Health Analytics, LLC; the Institute of Addiction Medicine; and Aetna Behavioral Health.
- Optimal Minimum Length Of Treatment In Opioid-Dependence With Buprenorphine (Abstract PMH62)5
- This study was conducted in partnership with ZRx Outcomes Research.
- This study was conducted in partnership with ZRx Outcomes Research.
- Optimal Minimum Length Of Treatment With Buprenorphine: An Analysis Of Resource Use And Costs After Medically Controlled Discontinuation (Abstract PMH58)6
- This study was conducted in partnership with ZRx Outcomes Research.
Data being presented at ICOO evaluate characteristics of care among patients with OUD in addition to opioid overdose (OD) patients to better identify opportunities for improving outcomes.
Sunday, June 5, 2016, 8:00 a.m. 6:00 p.m.
- A 10-year Retrospective Study of Opioid Overdoses among Patients in a Large Integrated Healthcare System (Poster 4)7
- This study was conducted in partnership with the Center for Health Research; Geisinger Clinic; Biomedical & Translational Informatics; Emergency Medicine Service Line; Central Division; and Interventional Pain Management Center.
Monday, June 6, 2016, 8:00 a.m. 6:00 p.m.
- Characteristics and Treatment Patterns of US Medicaid Patients with Opioid Use Disorder (Poster 43)8
- This study was conducted in partnership with Aventura Family Health Center and Truven Health Analytics.
About Opioid Dependence
Opioid dependence is a complex health condition with social, psychological, and biological contributing factors9,10 that can affect anyone.11 In 2014, more than 2.4 million people age twelve or older had a pain reliever or heroin use disorder in the United States.12 Opioid dependence is a chronic disease,13 and relapse can occur.14 Suppressing withdrawal symptoms and reducing cravings with medication-assisted treatment, together with counseling and behavioral therapy, may make treatment success more likely.15
About Indivior
Indivior is a global specialty pharmaceutical company with a 20-year legacy in patient advocacy, health policy and evidence-based best practice models that have helped to advance modern addiction treatment. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global opioid dependence portfolio, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and address other chronic diseases of addiction including opiate overdose, alcohol use disorders and cocaine intoxication. It also is pursuing novel product candidates in related mental health disorders such as schizophrenia. Headquartered in the United States in Richmond, Va., Indivior employs more than 700 individuals globally and its portfolio is available in over 40 countries worldwide. Visit www.Indivior.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations.
Various factors may cause differences between Indivior's expectations and actual results, including: factors affecting sales of Indivior products and any future products; the outcome of research and development activities; decisions by regulatory authorities regarding the Indivior Group's drug applications; the speed with which regulatory authorizations, pricing approvals and product launches may be achieved; the outcome of post-approval clinical trials; competitive developments; difficulties or delays in manufacturing; the impact of existing and future legislation and regulatory provisions on product exclusivity; trends toward managed care and healthcare cost containment; legislation or regulatory action affecting pharmaceutical product pricing, reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Indivior Group's products and product candidates; risks related to legal proceedings; the Indivior Group's ability to protect its patents and other intellectual property; the outcome of patent litigation relating to ongoing ANDA lawsuits; changes in governmental laws and regulations; issues related to the outsourcing of certain operational and staff functions to third parties; uncertainties related to general economic, political, business, industry, regulatory and market conditions; and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product recalls and withdrawals and other unusual items.
Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
1 Comprehensive Addiction and Recovery Act of 2016, S.524. 114th Congress (2015-2016). https://www.congress.gov/bill/114th-congress/senate-bill/524/text. Accessed March 2016.
2 Montejano LB, NA Ronquest, TM Willson, BA Wollschlaeger, AL Cole, VR Nadipelli. Truven Health Analytics, Indivior Inc., Aventura Family Health Center. How To Measure 'Opioid Relapse' In Real-World Claims Data (Abstract PRM6).
3 Tkacz Joseph, Brenna Brady, Vijay Nadipelli, BPharm MS, Joseph Volpicelli, Naoko Ronquest, Hyong Un, Charles Ruetsch. The Association Between Buprenorphine Medication-Assisted Treatment Adherence And Health Care Service Utilization And Costs (Abstract PMH31).
4 Brady Brenna, Joseph Tkacz, Vijay Nadipelli, Joseph Volpicelli, Naoko Ronquest, Hyong Un, Charles Ruetsch. Relapse In Opioid Use Disorder: Implications For Health Care Utilization And Costs (Abstract PMH35).
5 Zah V, N Matveev, M Berjan, J Ruby. Optimal Minimum Length Of Treatment In Opioid-Dependence With Buprenorphine (Abstract PMH62).
6 Zah V, N Matveev, M Berjan, J Ruby. Optimal Minimum Length Of Treatment With Buprenorphine: An Analysis Of Resource Use And Costs After Medically Controlled Discontinuation (Abstract PMH58).
7 A 10-year Retrospective Study of Opioid Overdoses among Patients in a Large Integrated Healthcare System.
8 Characteristics and Treatment Patterns of US Medicaid Patients with Opioid Use Disorder.
9 Kosten TR, George TOP. The Neurobiology of Opioid Dependence: Implications for Treatment. Sci Pract Perspect. Jul 2002;1(1):13-20. PMCID:PMC2851054.
10 World Health Organization. United Nations Office on Drugs and Crime, Joint United Nations Program on HIV/AIDS. Position paper. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. Geneva, Switzerland: World Health Organization; 2004.
11 Substance Abuse and Mental Health Services Administration. Characteristics of substance abuse treatment admissions reporting primary abuse of prescription painkillers: 1998 and 2008. The TEDS Report. Sept 23, 2010:1-6.
12 U.S. Department of Health and Human Services: Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality. Results from the 2014 National Survey on Drug Use and Health: Summary of National Findings. Sep 2015. http://www.mentalhealth.va.gov/providers/sud/docs/english_buprenorphine_facts.pdf. Accessed April 26, 2014.
13 U.S. Department of Health and Human Services: Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. The facts about BUPRENORPHINE for the treatment of opioid dependence 2009. Available at: http://www.mentalhealth.va.gov/providers/sud/docs/english_buprenorphine_facts.pdf. Accessed April 26, 2014.
14 Parran et al. Drug Alcohol Depend. 2010 January 1;106(1):56-60. Doi:10.1016/j.drugalcdep.2009.07.013.
15 National Institute on Drug Abuse. August 2010. Drugs, Brains, and Behavior: The Science of Addiction.
Logo: http://photos.prnewswire.com/prnh/20150728/248099LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/indivior-to-present-new-data-at-ispor-and-icoo-that-assess-implications-of-adherence-healthcare-service-utilization-and-costs-in-opioid-use-disorder-300272439.html
SOURCE Indivior PLC
